Further understanding of molecular mechanisms underlying the regulation of ASK1 activity will provide opportunities to identify novel therapeutic targets and to develop promising therapeutic compounds for treatment of NAFLD/NASH. Here, MAP3K5 is linked to metabolic dysfunction-associated steatohepatitis.